With work ongoing in the oncology community to develop the evidence needed to support circulating tumor DNA as a regulatory efficacy endpoint, one US Food and Drug Administration official is making a plea for standardization.
Developing the evidence needed to support use of a novel endpoint is a “heavy lift” requiring many stakeholders and pooling...







